中国直肠癌放射治疗指南(2020年版)

doi:10.3760/cma.j.cn371439-20210512-00076

摘要/Abstract

中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国直肠癌放射治疗指南(2020年版)[J]. 国际肿瘤学杂志, 2021, 48(7): 389-401.

图/表 5

表1

表2

图1

图2

图3

参考文献 71

[1]	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8):561-585. DOI: 10.3760/cma.j.cn112139-20200518-00390.
[2]	Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review[J]. Gastroenterology, 1993, 104(5):1535-1549. DOI: 10.1016/0016-5085(93)90368-m. pmid: 8482467
[3]	Ponz de Leon M, Sassatelli R, Benatti P, et al. Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry[J]. Cancer, 1993, 71(11):3493-3501. DOI: 10.1002/1097-0142(19930601)71:11<3493::aid-cncr2820711106>3.0.co;2-h. pmid: 8387880
[4]	Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer Susceptibility gene mutations in individuals with colorectal cancer[J]. J Clin Oncol, 2017, 35(10):1086-1095. DOI: 10.1200/JCO.2016.71.0012. doi: 10.1200/JCO.2016.71.0012 pmid: 28135145
[5]	Liu Z, Zhang Y, Niu Y, et al. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer[J]. PLoS One, 2014, 9(8):e103910. DOI: 10.1371/journal.pone.0103910. doi: 10.1371/journal.pone.0103910
[6]	O'Connell E, Galvin R, McNamara DA, et al. The utility of preoperative radiological evaluation of early rectal neoplasia: a systematic review and meta-analysis[J]. Colorectal Dis, 2020, 22(9):1076-1084. DOI: 10.1111/codi.15015. doi: 10.1111/codi.v22.9
[7]	Pappalardo G, Chiaretti M. Early rectal cancer: a choice between local excision and transabdominal resection. A review of the literature and current guidelines[J]. Ann Ital Chir, 2017, 88:183-189. doi: S0003469X1702680X pmid: 28346223
[8]	Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv22-iv40. DOI: 10.1093/annonc/mdx224.
[9]	Choi SH, Kim SY, Park SH, et al. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: systematic review and meta-analysis[J]. J Magn Reson Imaging, 2018, 47(5):1237-1250. DOI: 10.1002/jmri.25852. doi: 10.1002/jmri.v47.5
[10]	Daza JF, Solis NM, Parpia S, et al. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases[J]. Eur J Surg Oncol, 2019, 45(8):1341-1348. DOI: 10.1016/j.ejso.2019.03.025. doi: 10.1016/j.ejso.2019.03.025
[11]	Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer[J]. Int J Clin Oncol, 2020, 25(1):1-42. DOI: 10.1007/s10147-019-01485-z. doi: 10.1007/s10147-019-01485-z pmid: 31203527
[12]	D Souza N, de Neree Tot Babberich MPM, d'Hoore A, et al. Definition of the rectum: an international, expert-based Delphi consensus[J]. Ann Surg, 2019, 270(6):955-959. DOI: 10.1097/SLA.0000000000003251. doi: 10.1097/SLA.0000000000003251
[13]	Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group CSOCOC. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J]. Chin J Cancer Res, 2019, 31(1):117-134. DOI: 10.21147/j.issn.1000-9604.2019.01.07. doi: 10.21147/j.issn.1000-9604.2019.01.07
[14]	Beets-Tan RGH, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated re-commendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting[J]. Eur Radiol, 2018, 28(4):1465-1475. DOI: 10.1007/s00330-017-5026-2. doi: 10.1007/s00330-017-5026-2 pmid: 29043428
[15]	Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY Ⅱ study[J]. Ann Surg, 2016, 263(4):751-760. DOI: 10.1097/SLA.0000000000001193. doi: 10.1097/SLA.0000000000001193 pmid: 25822672
[16]	Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies[J]. Ann Surg, 2016, 263(3):458-464. DOI: 10.1097/SLA.0000000000000368. doi: 10.1097/SLA.0000000000000368 pmid: 24263329
[17]	Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, rando-mized, controlled trial (GRECCAR-6)[J]. J Clin Oncol, 2016, 34(31):3773-3780. DOI: 10.1200/JCO.2016.67.6049. doi: 10.1200/JCO.2016.67.6049
[18]	Seo N, Kim H, Cho MS, et al. Response assessment with MRI after chemoradiotherapy in rectal cancer: current evidences[J]. Korean J Radiol, 2019, 20(7):1003-1018. DOI: 10.3348/kjr.2018.0611. doi: 10.3348/kjr.2018.0611
[19]	Van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139):2537-2545. DOI: 10.1016/S0140-6736(18)31078-X. doi: 10.1016/S0140-6736(18)31078-X
[20]	Sclafani F, Brown G, Cunningham D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer[J]. Br J Cancer, 2017, 117(10):1478-1485. DOI: 10.1038/bjc.2017.320. doi: 10.1038/bjc.2017.320
[21]	Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188. DOI: 10.1111/his.13975. doi: 10.1111/his.13975 pmid: 31433515
[22]	Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med, 2004, 351(17):1731-1740. DOI: 10.1056/NEJMoa040694. doi: 10.1056/NEJMoa040694
[23]	Keller DS, Berho M, Perez RO, et al. The multidisciplinary management of rectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(7):414-429. DOI: 10.1038/s41575-020-0275-y. doi: 10.1038/s41575-020-0275-y
[24]	Afshari K, Chabok A, Naredi P, et al. Prognostic factors for survival in stage Ⅳ rectal cancer: a Swedish nationwide case-control study[J]. Surg Oncol, 2019, 107(5):102-106. DOI: 10.1016/j.suronc.2019.04.005.
[25]	Kok END, Havenga K, Tanis PJ, et al. Multicentre study of short-course radiotherapy, systemic therapy and resection/ablation for stage Ⅳ rectal cancer[J]. Br J Surg, 2020, 107(5):537-545. DOI: 10.1002/bjs.11418. doi: 10.1002/bjs.11418 pmid: 32017049
[26]	Detering R, Karthaus EG, Borstlap WAA, et al. Treatment and survival of locally recurrent rectal cancer: a cross-sectional population study 15 years after the Dutch TME trial[J]. Eur J Surg Oncol, 2019, 45(11):2059-2069. DOI: 10.1016/j.ejso.2019.06.016. doi: S0748-7983(19)30510-4 pmid: 31230980
[27]	Hagemans JAW, van Rees JM, Alberda WJ, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre[J]. Eur J Surg Oncol, 2020, 46(3):448-454. DOI: 10.1016/j.ejso.2019.10.037. doi: S0748-7983(19)30917-5 pmid: 31761506
[28]	NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer, Version 1. 2020[EB/OL]. [2021-04-28]. http://www.nccn.org/.
[29]	Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, rando-mised, phase 3 trial[J]. Lancet Oncol, 2015, 16(8):979-989. DOI: 10.1016/S1470-2045(15)00159-X. doi: 10.1016/S1470-2045(15)00159-X
[30]	Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial[J]. Lancet Oncol, 2012, 13(6):579-588. DOI: 10.1016/S1470-2045(12)70116-X. doi: 10.1016/S1470-2045(12)70116-X
[31]	Liu WY, Jin J, Tang Y, et al. Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: a planned interim analysis of a multicenter, phase Ⅱ trial[J]. J Geriatr Oncol, 2021, 12(4):572-577. DOI: 10.1016/j.jgo.2020.10.016. doi: 10.1016/j.jgo.2020.10.016
[32]	O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal can-cer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04[J]. J Clin Oncol, 2014, 32(18):1927-1934. DOI: 10.1200/JCO.2013.53.7753. doi: 10.1200/JCO.2013.53.7753 pmid: 24799484
[33]	Schmoll HJ, Stein A, Van Cutsem E, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD[J]. J Clin Oncol, 2021, 39(1):17-29. DOI: 10.1200/JCO.20.01740.
[34]	Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poorprognosis locally advanced rectal cancer: the AVACROSS study[J]. Oncologist, 2011, 16(5):614-620. DOI: 10.1634/theoncologist.2010-0285. doi: 10.1634/theoncologist.2010-0285
[35]	Sclafani F, Brown G, Cunningham D, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemo-radiotherapy in MRI-defined, locally advanced rectal cancer[J]. Ann Oncol, 2016, 27(8):1557-1565. DOI: 10.1093/annonc/mdw215. doi: 10.1093/annonc/mdw215 pmid: 27217542
[36]	Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial[J]. J Clin Oncol, 2019, 37(34):3223-3233. DOI: 10.1200/JCO.18.02309. doi: 10.1200/JCO.18.02309
[37]	Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T₃ rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04[J]. J Clin Oncol, 2012, 30(31):3827-3833. DOI: 10.1200/JCO.2012.42.9597. doi: 10.1200/JCO.2012.42.9597
[38]	Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer-the RAPIDO trial[J]. BMC Cancer, 2013, 13:279. DOI: 10.1186/1471-2407-13-279. doi: 10.1186/1471-2407-13-279 pmid: 23742033
[39]	Cella L, Ciscognetti N, Martin G, et al. Preoperative radiation treatment for rectal cancer: comparison of target coverage and small bowel NTCP in conventional vs. 3D-conformal planning.[J]. Med Dosim, 2009, 34(1):75-81. DOI: 10.1016/j.meddos.2008.04.001. doi: 10.1016/j.meddos.2008.04.001
[40]	Kim TH, Chie EK, Kim DY, et al. Comparison of the belly board device method and the distended bladder method for reducing irradiated small bowel volumes in preoperative radiotherapy of rectal cancer patients[J]. Int J Radiat Oncol Biol Phys, 2005, 62(3):769-775. DOI: 10.1016/j.ijrobp.2004.11.015. doi: 10.1016/j.ijrobp.2004.11.015
[41]	O'Neill BD, Salerno G, Thomas K, et al. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy[J]. Br J Radiol, 2009, 82(978):509-513. DOI: 10.1259/bjr/60198873. doi: 10.1259/bjr/60198873 pmid: 19153180
[42]	中国医师协会结直肠肿瘤专委会放疗专委会, 中华医学会放射肿瘤治疗学分会, 唐源, 等. 直肠癌术前/术后适形/调强放疗靶区勾画共识与图谱[J]. 中华放射肿瘤学杂志, 2018, 27(3):227-234. DOI: 10.3760/cma.j.issn.1004-4221.2018.03.001.
[43]	Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 rando-mised trials[J]. Lancet, 2001, 358(9290):1291-1304. DOI: 10.1016/S0140-6736(01)06409-1. doi: 10.1016/S0140-6736(01)06409-1
[44]	Sauer R, Fietkau R, Wittekind C, et al. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94[J]. Colorectal Dis, 2003, 5(5):406-415. DOI: 10.1046/j.1463-1318.2003.00509.x. pmid: 12925071
[45]	Gao YH, Lin JZ, An X, et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2014, 90(5):1153-1160. DOI: 10.1016/j.ijrobp.2014.07.021. doi: 10.1016/j.ijrobp.2014.07.021
[46]	Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J]. JAMA Onco, 2018, 4(6):e180071. DOI: 10.1001/jamaoncol.2018.0071.
[47]	Zaborowski A, Stakelum A, Winter DC. Systematic review of outcomes after total neoadjuvant therapy for locally advanced rectal can-cer[J]. Br J Surg, 2019, 106(8):979-987. DOI: 10.1002/bjs.11171. doi: 10.1002/bjs.11171 pmid: 31074508
[48]	张术, 王小豪, 肖巍魏, 等. 高剂量放疗联合化疗治疗直肠癌的临床分析[J]. 实用肿瘤杂志, 2018, 33(2):102-107.
[49]	Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study[J]. Lancet Oncol, 2015, 16(8):919-927. DOI: 10.1016/S1470-2045(15)00120-5. doi: 10.1016/S1470-2045(15)00120-5
[50]	Dizdarevic E, Frøstrup Hansen T, Pløen J, et al. Long-term patient-reported outcomes after high-dose chemoradiation therapy for nonsurgical management of distal rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 106(3):556-563. DOI: 10.1016/j.ijrobp.2019.10.046. doi: 10.1016/j.ijrobp.2019.10.046
[51]	Marks LB, Ten Haken RK, Martel MK. Guest editor's introduction to QUANTEC: a users guide[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl):S1-S2. DOI: 10.1016/j.ijrobp.2009.08.075. doi: 10.1016/j.ijrobp.2009.08.075
[52]	Jadon R, Higgins E, Hanna L, et al. A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy[J]. Radiat Oncol, 2019, 14(1):57. DOI: 10.1186/s13014-019-1262-8. doi: 10.1186/s13014-019-1262-8
[53]	McCormack S, Diffey J, Andrew Morgan A. The effect of gantry angle on megavoltage photon beam attenuation by a carbon fiber couch insert[J]. Med Phys, 2005, 32(2):483-487. DOI: 10.1118/1.1852792. pmid: 15789595
[54]	Kanai T, Furuichi W, Mori S. Evaluation of patient positional reproducibility on the treatment couch and its impact on dose distribution using rotating gantry system in scanned carbon-ion beam therapy[J]. Phys Med, 2019, 57:160-168. DOI: 10.1016/j.ejmp.2018.12.013. doi: 10.1016/j.ejmp.2018.12.013
[55]	Holyoake DLP, Partridge M, Hawkins MA. Systematic review and meta-analysis of small bowel dose-volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy[J]. Radiother Oncol, 2019, 138:38-44. DOI: 10.1016/j.radonc.2019.05.001. doi: S0167-8140(19)30400-1 pmid: 31136961
[56]	Mihaylov IB, Fatyga M, Bzdusek K, et al. Biological optimization in volumetric modulated arc radiotherapy for prostate carcinoma[J]. Int J Radiat Oncol Biol Phys, 2012, 82(3):1292-1298. DOI: 10.1016/j.ijrobp.2010.06.020. doi: 10.1016/j.ijrobp.2010.06.020
[57]	Vieillot S, Azria D, Lemanski C, et al. Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer[J]. Radiat Oncol, 2010, 5:92. DOI: 10.1186/1748-717X-5-92. doi: 10.1186/1748-717X-5-92 pmid: 20942958
[58]	Appelt AL, Sebag-Montefiore D. Technological advances in radiothe-rapy of rectal cancer: opportunities and challenges[J]. Curr Opin Oncol, 2016, 28(4):353-358. DOI: 10.1097/CCO.00000000-00000306. doi: 10.1097/CCO.0000000000000306 pmid: 27153356
[59]	Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial[J]. Lancet Oncol, 2015, 16(8):957-966. DOI: 10.1016/S1470-2045(15)00004-2. doi: 10.1016/S1470-2045(15)00004-2
[60]	Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase Ⅱ randomized trial?[J]. Ann Oncol, 2015, 26(8):1722-1728. DOI: 10.1093/annonc/mdv223. doi: 10.1093/annonc/mdv223 pmid: 25957330
[61]	汪涛, 刘梅, 杨华良, 等. 自拟放射性肠炎灌肠液灌肠对急性放射性肠炎小鼠肠道黏膜屏障损伤的预防及治疗作用观察[J]. 山东医药, 2019, 59(27):38-41. DOI: 10.3969/j.issn.1002-266X.2019.27.010.
[62]	邹文爽, 安颂歌, 熊壮, 等. 中药保留灌肠治疗放射性直肠炎疗效的Meta分析[J]. 现代中西医结合杂志, 2015, 24(21):2309-2313. DOI: 10.3969/j.issn.1008-8849.2015.21.
[63]	殷剑明, 徐伯平, 冯惠霞, 等. 单味黄芩防治急性放射性皮炎的临床观察[J]. 中国中西医结合杂志, 2001, 21(4):304. DOI: 10.3321/j.issn:1003-5370.2001.04.022.
[64]	Lanciano R, Lamond J, Yang J, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors[J]. Front Oncol, 2012, 2:23. DOI: 10.3389/fonc.2012.00023.
[65]	Zhao J, Yorke ED, Li L, et al. Simple factors associated with radiation induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies[J]. Int J Radiat Oncol Biol Phys, 2016, 95(5):1357-1366. DOI: 10.1016/j.ijrobp.2016.03.024. doi: 10.1016/j.ijrobp.2016.03.024
[66]	Lu X, Cai Y, Xia L, et al. Treatment modalities and relative survival in patients with brain metastasis from colorectal cancer[J]. Biosci Trends, 2019, 13(2):182-188. DOI: 10.5582/bst.2019.01044. doi: 10.5582/bst.2019.01044
[67]	Lai HW, Wei JC, Hung HC, et al. Impact of treatment modality on clinical outcome in metastatic colorectal cancer patients stratified by metastatic sites[J]. Postgrad Med, 2019, 13(2):163-170. DOI: 10.1080/00325481.2019.1568016.
[68]	Hagemans JAW, van Rees JM, Alberda WJ, et al. Locally recurrent rectal cancer: long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre[J]. Eur J Surg Oncol, 2020, 46(3):448-454. DOI: 10.1016/j.ejso.2019.10.037. doi: S0748-7983(19)30917-5 pmid: 31761506
[69]	Westberg K, Palmer G, Hjern F, et al. Management and prognosis of locally recurrent rectal cancer—a national population-based study[J]. Eur J Surg Oncol, 2018, 44(1):100-107. DOI: 10.1016/j.ejso.2017.11.013. doi: S0748-7983(17)30975-7 pmid: 29224985
[70]	Al-Haidari G, Skovlund E, Undseth C, et al. Re-irradiation for recurrent rectal cancer—a single-center experience[J]. Acta Oncol, 2020, 59(5):534-540. DOI: 10.1080/0284186X.2020.1725111. doi: 10.1080/0284186X.2020.1725111 pmid: 32056476
[71]	Dowing A, Morris EJ, Ricards M, et al. Health-related quality of life after colorectal cancer in England: a patient-reported outcomes study of individuals 12 to 36 months after diagnosis[J]. J Clin Oncol, 2015, 33(6):616-624. DOI: 10.1200/JCO.2014.56.6539.

项目	盆腔骶前区	直肠系膜区	髂内淋巴引流区	闭孔淋巴引流区	髂外淋巴引流区	肛门括约肌复合体	坐骨直肠窝	腹股沟淋巴引流区
cT₃N₀,高位	+	+	+
cT₃N₀,中低位^a	+	+	+			+(肛管受侵)	^c	^d
任何T,直肠系膜/骶前淋巴结转移	+	+	+	+		+(肛管受侵)	^c	^d
任何T,髂内淋巴结转移	+	+	+	+		+(肛管受侵)	^c	^d
任何T,闭孔淋巴结转移	+	+	+	+	+	+(肛管受侵)	^c	^d
cT₄,前盆腔器官受侵^b	+	+	+	+	+	+(肛管受侵)	^c	^d

项目	Dixon术后	Miles术后
吻合口/会阴瘢痕	+(吻合口)	+(会阴瘢痕)
瘤床	+	+
骶前区+直肠系膜区+ 髂内淋巴引流区^a	+	+
闭孔淋巴引流区	+	+
髂外淋巴引流区	-	-
腹股沟淋巴引流区	-	-
坐骨直肠窝	+(肿瘤中心距肛门缘6 cm以内)	+
肛门括约肌复合体		已切除

中国直肠癌放射治疗指南(2020年版)

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 71

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[5]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[9]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[10]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[11]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[12]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[13]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[14]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[15]	曾利武, 杜雨强, 张鹏, 陶凯雄. 直肠癌侧方淋巴结转移的影像评估进展[J]. 国际肿瘤学杂志, 2023, 50(4): 248-251.